This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Conceptus(R) Receives FDA Approval On Essure’s Bilateral Placement Rate To 96.9%

Conceptus Inc. (NASDAQ: CPTS), developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.

The bilateral placement rate, at first attempt, has increased from 94.6% to 96.9%; and the hysteroscopic time decreased from thirteen to nine minutes based on a clinical study in a commercial setting with 94 physicians treating 612 patients. The post-approval study was designed to evaluate bilateral placement rate and ease-of-use of the ESS305 after its July 2007 introduction. This improved labeling offers patients and physicians with even more security of placing the micro-inserts properly the first time and ease of performing the procedure.

“The announcement of an increased bilateral placement rate and faster procedure time illustrates the continued commitment of Conceptus to improve an already simple procedure for both the benefit of physicians and patients,” said Dr. Mark Levie, an OB/GYN based in New York City. “In my opinion, Essure continues to be the choice for physicians and women seeking a permanent birth control solution.”

During the procedure, a physician places two soft, flexible micro-inserts into each fallopian tube through the cervix without incisions. Essure is 99.74% effective based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market.

Mark Sieczkarek, president and chief executive officer of Conceptus Inc. states, “The improvements to our product were a direct response to customer input. The objective to provide an even simpler and faster procedure was met as shown by FDA approval of our updated labeling. Conceptus continues to be dedicated to providing ‘best in class’ innovative solutions in women’s healthcare.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%
YHOO $27.05 -3.29%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs